File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
  • Basic View
  • Metadata View
  • XML View
TitleBosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
 
AuthorsMok, MY1
Tsang, PL1
Lam, YM1
Lo, Y1
Wong, WS1
Lau, CS1
 
Issue Date2007
 
PublisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
 
CitationLupus, 2007, v. 16 n. 4, p. 279-285 [How to Cite?]
DOI: http://dx.doi.org/10.1177/0961203307076509
 
AbstractPulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE) is uncommon but is associated with poor survival. This study aimed to examine the long-term effects of bosentan, a dual endothelin-1 receptor antagonist, on symptomatology, haemodynamics and quality of life measures in SLE patients with symptomatic PAH. Four local patients had been followed up prospectively with pre-defined protocol during 12-months of bosentan treatment. Six minute walk distance (6MWD), NYHA functional class, Borg Dyspnoea Index (BDI) and SF-36 were measured at 0, 3, 6, 9 and 12 months. Systolic pulmonary arterial pressure (PAP) was measured by transthoracic echocardiography at zero, six and 12 months. Clinical parameters were analysed, pooling data from other SLE patients reported in the literature (n = 4). Bosentan was found to result in significant improvement in 6MWD compared to baseline [+24.8 m, +26.2 m, +54 m and +62.7 m at three (P = 0.001), six (P = 0.001), nine (P = 0.24) and 12 (P = 0.01) months respectively]. A differential effect was found with greater response in patients with lower exercise capacity. This was accompanied by decrease in NYHA functional class, BDI, transient or sustained drop in systolic PAP and mild improvement in SF-36 domains including mental health, vitality, social function and general health. Significantly deranged liver function was found in one patient. © 2007 SAGE Publications.
 
ISSN0961-2033
2013 Impact Factor: 2.481
 
DOIhttp://dx.doi.org/10.1177/0961203307076509
 
ISI Accession Number IDWOS:000246669200007
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorMok, MY
 
dc.contributor.authorTsang, PL
 
dc.contributor.authorLam, YM
 
dc.contributor.authorLo, Y
 
dc.contributor.authorWong, WS
 
dc.contributor.authorLau, CS
 
dc.date.accessioned2010-09-06T07:34:00Z
 
dc.date.available2010-09-06T07:34:00Z
 
dc.date.issued2007
 
dc.description.abstractPulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE) is uncommon but is associated with poor survival. This study aimed to examine the long-term effects of bosentan, a dual endothelin-1 receptor antagonist, on symptomatology, haemodynamics and quality of life measures in SLE patients with symptomatic PAH. Four local patients had been followed up prospectively with pre-defined protocol during 12-months of bosentan treatment. Six minute walk distance (6MWD), NYHA functional class, Borg Dyspnoea Index (BDI) and SF-36 were measured at 0, 3, 6, 9 and 12 months. Systolic pulmonary arterial pressure (PAP) was measured by transthoracic echocardiography at zero, six and 12 months. Clinical parameters were analysed, pooling data from other SLE patients reported in the literature (n = 4). Bosentan was found to result in significant improvement in 6MWD compared to baseline [+24.8 m, +26.2 m, +54 m and +62.7 m at three (P = 0.001), six (P = 0.001), nine (P = 0.24) and 12 (P = 0.01) months respectively]. A differential effect was found with greater response in patients with lower exercise capacity. This was accompanied by decrease in NYHA functional class, BDI, transient or sustained drop in systolic PAP and mild improvement in SF-36 domains including mental health, vitality, social function and general health. Significantly deranged liver function was found in one patient. © 2007 SAGE Publications.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationLupus, 2007, v. 16 n. 4, p. 279-285 [How to Cite?]
DOI: http://dx.doi.org/10.1177/0961203307076509
 
dc.identifier.doihttp://dx.doi.org/10.1177/0961203307076509
 
dc.identifier.epage285
 
dc.identifier.hkuros134353
 
dc.identifier.isiWOS:000246669200007
 
dc.identifier.issn0961-2033
2013 Impact Factor: 2.481
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid17439935
 
dc.identifier.scopuseid_2-s2.0-34249015268
 
dc.identifier.spage279
 
dc.identifier.urihttp://hdl.handle.net/10722/77631
 
dc.identifier.volume16
 
dc.languageeng
 
dc.publisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofLupus
 
dc.relation.referencesReferences in Scopus
 
dc.rightsLupus. Copyright © Sage Publications Ltd.
 
dc.subject.meshAdult
 
dc.subject.meshAntihypertensive Agents - therapeutic use
 
dc.subject.meshBlood Pressure - drug effects
 
dc.subject.meshExercise Tolerance
 
dc.subject.meshFemale
 
dc.subject.meshHumans
 
dc.subject.meshHypertension, Pulmonary - complications - drug therapy
 
dc.subject.meshLupus Erythematosus, Systemic - complications
 
dc.subject.meshMiddle Aged
 
dc.subject.meshQuality of Life
 
dc.subject.meshSeverity of Illness Index
 
dc.subject.meshSulfonamides - therapeutic use
 
dc.subject.meshTreatment Outcome
 
dc.titleBosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Mok, MY</contributor.author>
<contributor.author>Tsang, PL</contributor.author>
<contributor.author>Lam, YM</contributor.author>
<contributor.author>Lo, Y</contributor.author>
<contributor.author>Wong, WS</contributor.author>
<contributor.author>Lau, CS</contributor.author>
<date.accessioned>2010-09-06T07:34:00Z</date.accessioned>
<date.available>2010-09-06T07:34:00Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Lupus, 2007, v. 16 n. 4, p. 279-285</identifier.citation>
<identifier.issn>0961-2033</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/77631</identifier.uri>
<description.abstract>Pulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE) is uncommon but is associated with poor survival. This study aimed to examine the long-term effects of bosentan, a dual endothelin-1 receptor antagonist, on symptomatology, haemodynamics and quality of life measures in SLE patients with symptomatic PAH. Four local patients had been followed up prospectively with pre-defined protocol during 12-months of bosentan treatment. Six minute walk distance (6MWD), NYHA functional class, Borg Dyspnoea Index (BDI) and SF-36 were measured at 0, 3, 6, 9 and 12 months. Systolic pulmonary arterial pressure (PAP) was measured by transthoracic echocardiography at zero, six and 12 months. Clinical parameters were analysed, pooling data from other SLE patients reported in the literature (n = 4). Bosentan was found to result in significant improvement in 6MWD compared to baseline [+24.8 m, +26.2 m, +54 m and +62.7 m at three (P = 0.001), six (P = 0.001), nine (P = 0.24) and 12 (P = 0.01) months respectively]. A differential effect was found with greater response in patients with lower exercise capacity. This was accompanied by decrease in NYHA functional class, BDI, transient or sustained drop in systolic PAP and mild improvement in SF-36 domains including mental health, vitality, social function and general health. Significantly deranged liver function was found in one patient. &#169; 2007 SAGE Publications.</description.abstract>
<language>eng</language>
<publisher>Sage Publications Ltd. The Journal&apos;s web site is located at http://lup.sagepub.com</publisher>
<relation.ispartof>Lupus</relation.ispartof>
<rights>Lupus. Copyright &#169; Sage Publications Ltd.</rights>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Antihypertensive Agents - therapeutic use</subject.mesh>
<subject.mesh>Blood Pressure - drug effects</subject.mesh>
<subject.mesh>Exercise Tolerance</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Hypertension, Pulmonary - complications - drug therapy</subject.mesh>
<subject.mesh>Lupus Erythematosus, Systemic - complications</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Quality of Life</subject.mesh>
<subject.mesh>Severity of Illness Index</subject.mesh>
<subject.mesh>Sulfonamides - therapeutic use</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<title>Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0961-2033&amp;volume=16&amp;issue=4&amp;spage=279&amp;epage=285&amp;date=2007&amp;atitle=Bosentan+Use+in+Systemic+Lupus+Erythematosus+Patients+with+Pulmonary+Arterial+Hypertension</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1177/0961203307076509</identifier.doi>
<identifier.pmid>17439935</identifier.pmid>
<identifier.scopus>eid_2-s2.0-34249015268</identifier.scopus>
<identifier.hkuros>134353</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-34249015268&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>16</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>279</identifier.spage>
<identifier.epage>285</identifier.epage>
<identifier.isi>WOS:000246669200007</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. Queen Mary Hospital Hong Kong